Peroxisome proliferators induce apoptosis and decrease DNA synthesis in hepatoma cell lines

Human and Experimental Toxicology

Volumn 19, Issue 3, 2000, Pages 193-202

  Goll, V ^a   Viollon Abadie, C ^a   Nicod, L ^a   Richert, L ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Apoptosis; DNA synthesis; Enzyme activities; Hepatoma cell lines; Human; Peroxisome proliferators; Rat

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; DNA; NAFENOPIN; PEROXISOME PROLIFERATOR; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

APOGON BRACHYGRAMMUS;

EID: 0034131387     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032700678827753     Document Type: Article

References (50)

1. Goll V et al. Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis and apoptosis in rat and human hepatocyte cultures. Toxicology and Applied Pharmacology 1999; 160: 21-32.
2. Foxworthy PS, Eacho PI. Conditions influencing the induction of peroxisomal β-oxidation in cultured rat hepatocytes. Toxicology Letters 1986; 30: 189-196.
3. Sharma R, Lake BG, Gibson GG. Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid β-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Biochemical Pharmacology 1988; 37: 1203-1206.
4. Foxworthy PS, White SL, Hoover DM, Eacho PI. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal β-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicology and Applied Pharmacology 1990; 104: 386-394.
5. Lake BG. Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Annual Review of Pharmacology and Toxicology 1995; 35: 483-507.
6. Lake BG. Peroxisome proliferation: current mechanisms relating to non-genotoxic carcinogenesis. Toxicology Letters 1995; 82/83: 673-681.
7. Oliver MF, Heady JA, Morris JN, Cooper J. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; 8403: 600-605.
8. Foxworthy PS, Perry DN, Eacho PI. Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs. Toxicology and Applied Pharmacology 1993; 118: 271-274.
9. Huber WW, Grasl-Kraupp B, Schulte-Hermann R. Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Critical Review in Toxicology 1996; 26: 365-481.
10. Bentley P et al. Hepatic peroxisome proliferation in rodents and its significance for humans. Food and Chemical Toxicology 1993; 31: 857-907.
11. Parzefall W, Erber E, Sedivy R, Schulte-Hermann R. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters. Cancer Research 1991; 51: 1143-1147.
12. James NH, Roberts RA. Species differences in the clonal expansion of hepatocytes in response to the coaction of epidermal growth factor and nafenopin, a rodent hepatocarcinogenic peroxisome proliferator. Fundamental Applied Toxicology 1995; 26: 143-149.
13. Deschatrette J, Weiss MC. Characterisation of differentiated and dedifferentiated clones of rat hepatoma. Biochimie 1974; 56: 1603-1611.
14. Javitt NB. HepG2 cells as a resource for metabolic studies: lipoprotein, cholesterol and bile acids. FASEB 1990; 4: 161-168.
15. Bayly AC, French NJ, Dive C, Roberts RA. Non-genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. Journal of Cell Science 1993; 104: 307-315.
16. Doostdar H et al. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HepG2 hepatoma cells. Biochemical Pharmalogy 1993; 4: 629-635.
17. Alexandre E et al. Expression of cytochromes P-450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells - Effect of ethanol. Toxicology in vitro 1999; 13: 427-435.
18. Brocard C et al. Stimulation of poroxisomal palmitoyl-CoA oxidase activity by ciprofibrate in hepatic cell lines: comparative studies in FaO, MH1C1 and HepG2 cells. Biology of the Cell 1993; 77: 37-41.
19. Scotto C, Keller JM, Schohn H, Dauça M. Comparative effects of clofibrate on peroxisomal enzymes of human (Hep EBNA2) and rat (FaO) hepatoma cell lines. European Journal of Cell Biology 1995; 66: 375-381.
20. Duclos S, Bride J, Ramirez LC, Bournot P. Peroxisome proliferation and β-oxidation in FaO and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate. European Journal of Cell Biology 1997; 72: 314-323.
21. Passilly P, Jannin B, Hassell S, Latruffe N. Human HepG2 and rat FaO hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry. Experimental Cell Research 1996; 223: 436-442.
22. Gill HJ et al. The rodent non-genotoxic hepatocarcinogen nafenopin and EGF alter the mitosis/apoptosis balance promoting hepatoma cell clonal growth. Cell Death and Differentiation 1995; 2: 211-217.
23. Canuto RA et al. Rapid and extensive lethal action of clofibrate on hepatoma cells in vitro. Cell Death and Differentiation 1997; 4: 224-232.
24. Canuto RA et al. Peroxisome proliferators induce apoptosis in hepatoma cells. Cancer Detection and Prevention 1998; 22: 357-366.
25. Bayly AC, Roberts RA, Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. Journal of Cell Biology 1994; 125: 197-203.
26. Lim IK et al. Protection of 5α-dihydrotestosterone against TGFβ-induced apoptosis in FaO cells and induction of mitosis in HepG2 cells. International Journal of Cancer 1997; 72: 351-355.
27. Gressner AM, Lahme B, Mannherz HG, Plozar B. TGFβ-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. Journal of Hepatology 1997; 26: 1079-1092.
28. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Research 1992; 52: 385-388.
29. Chuang LY, Hung WC, Chang CC, Tsai JH. Characterization of apoptosis induced by transforming growth factor β1 in human hepatoma cells. Anticancer Research 1994; 14: 147-152.
30. Huang YL, Chou CK. Bcl-2 blocks apoptotic signal of transforming growth factor-β in human hepatoma cells, Journal of Biomedical Science 1998; 5: 185-191.
31. Doostdar H et al. Variation in drug metabolizing enzyme activities during the growth of human HepG2 hepatoma cells. Xenobiotica 1990; 20: 435-441.
32. Carmichael J et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay assessment of chemosensitivity testing. Cancer Research 1987; 47: 936-942.
33. Gray TJB et al. Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology 1983; 67: 15-25.
34. Richert L et al. Comparison of the induction of hepatic peroxisome proliferation by the herbicide oxadiazon in vivo in rats, mice, and dogs and in vitro in rat and human hepatocytes. Toxicology and Applied Pharmacology 1996; 141: 35-43.
35. Bichet N et al. Comparison of peroxisome proliferation in rat and human hepatocytes in primary cultures. Toxicology and Applied Pharmacology 1990; 106: 509-517.
36. Blaauboer BJ et al. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology 1990; 40: 521-528.
37. Perrone CE, Shao L, Williams GM. Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicology and Applied Pharmacology 1998; 150: 277-286.
38. Leist M et al. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. The Journal of Immunology 1994; 153: 1778.
39. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Letters 1991; 291: 229-232.
40. Shiota G et al. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proceedings of the National Academy of Science, USA 1992; 89: 373-377.
41. Motoki Y et al. Decreased hepatocyte growth factor level by Wy-14,643, non-genotoxic hepatocarcinogen in F-344 rats. Carcinogenesis 1997; 8: 1303-1309.
42. Grisham JW, Tasao M, Lee DC, Shelton H. Sequential changes in epidermal growth factor receptors/ligand function in cultured rat liver epithelial cells transformed chemically in vitro. Pathobiology 1990; 58: 3-14.
43. Johannson S, Andersson N, Andersson G. Pretranslational and posttranslational regulation of the EGF receptor during the prereplicative phase of liver regeneration. Hepatology 1990; 12: 533-541.
44. Nelsestuen GL, Bazzi MD. Activation and regulation of protein kinase C enzymes. Journal of Bioenergetics and Biomembranes 1991; 23; 43-61.
45. Bieri F et al. Mechanistic studies on the mitogenic response induced in hepatocytes by nafenopin, a non-mutagenic hepatocarcinogen. Human and Experimental Toxicology 1991; 10: 86-87.
46. Dive C, Evans CA, Whetton AD. Induction of apoptosis - new targets for cancer chemotherapy. Seminars in Cancer Biology 1992; 3: 417-427.
47. Ducher L et al. Differential expression of five protein kinase C isoenzymes in FaO and HepG2 hepatoma cell lines compared with normal rat hepatocytes. Biochemical and Biophysical Research Communications 1995; 214: 546-553.
48. Bronfman M et al. Potentiation of diacylglycerol-activated protein kinase C by acyl-coenzyme A thioesters of hypolipidemic drugs. Biochemical and Biophysical Research Communications 1989; 159: 1026-1031.
49. Orellana A et al. Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of epidermal-growth-factor receptor in isolated rat hepatocytes. European Journal of Biochemistry 1993; 215: 903-906.
50. Passily P, Jannin B, Latruffe N. Influence of peroxisome proliferators on phosphoprotein levels in human and rat hepatic-derived cell lines. European Journal of Biochemistry 1995; 230: 316-321.